Evolving our approach to COVID-19 vaccines and treatments

6 December 2023 - As New Zealand’s response to the COVID-19 pandemic has evolved, so has ours. ...

Read more →

PHARMAC’s new equity policy

6 December 2023 - PHARMAC is drafting its first Equity Policy which outlines the mahi PHARMAC does, can do, or needs ...

Read more →

Informing real-time decisions with post-market drug evidence

10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...

Read more →

PHARMAC needs to work for patients, not itself

10 October 2023 - “The internal chaos and siege mentality at PHARMAC is exactly why the next Government needs to ...

Read more →

Review of cancer related surrogate outcomes used for PBAC decision-making

8 September 2023 - Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support ...

Read more →

Australia knocks back application for diabetes drug that could overshadow Ozempic

29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...

Read more →

PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist

29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the ...

Read more →

Pilot expert committee to support decision-making across the drug life cycle

8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...

Read more →

Prioritising patients in negotiations over drug pricing

14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...

Read more →

Clarity around PHARMAC’s priority lists

30 March 2023 - PHARMAC released its first Clarity Report, containing the latest information about medicines, vaccines, and related products ...

Read more →

Our progress in the funding of medicines for rare disorders

3 March 2023 - PHARMAC will hear from people affected by rare disorders in its upcoming Rare Disorders Advisory Committee meeting ...

Read more →

Speeding up access to new medicines in Scotland: abbreviated process

8 February 2023 - A process brought in to streamline decision-making around access to new medicines in NHSScotland during the ...

Read more →

NICE’s new methods reflect society’s values

4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...

Read more →

EQ-5D-Y-3L value sets, valuation methods and conceptual questions

12 December 2022 - The measurement and valuation of child health-related quality of life is a rapidly evolving field. ...

Read more →

Can we use existing guidance to support the development of robust real world evidence for health technology assessment/payer decision-making?

2 November 2022 - Advances in the digitisation of health systems and expedited regulatory approvals of innovative treatments have led to ...

Read more →